Abstract
Fluoroquinolones have been used increasingly in clinical medicine in the United States since the approval of norfloxacin, the first of these agents, by the U.S. Food and Drug Administration in 1986. Approvals of ciprofloxacin, ofloxacin, temafloxacin, lomefloxacin, and enoxacin followed, and other fluoroquinolones are under development. Although a nonfluorinated quinolone, nalidixic acid, has been available since the 1960s, its use was limited to treatment of urinary tract infections. Because of their greater potency and spectrum of activity and their extensive tissue distribution, many of the fluoroquinolones have been used to treat a broad range of infections at different body sites. Because of economic pressures, it is likely that oral antibiotics like the fluoroquinolones will be relied on increasingly in the future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
M. Gellert, DNA topoisomerases, Annu Rev Biochem. 50: 879 (1981).
R.J. Reece and A. Maxwell, DNA gyrase: structure and function, Crit Rev Biochem Molec Biol. 26: 335 (1991).
K.N. Kreuzer and N.R. Cozzarelli, Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth, J Bacteriol. 140: 424 (1979).
D.C. Hooper and J.S. Wolfson, Mechanisms of quinolone action and bacterial killing, in: “Quinolone Antimicrobial Agents,” Second Edition, D.C. Hooper and J.W. Wolfson, eds., American Society for Microbiology, Washington (1993).
H. Nikaido, Role of permeability barriers in resistance to J3-lactam antibiotics, Pharmacol Ther. 27: 197 (1985).
J.S. Chapman and N.H. Georgopadakou, Routes of quinolonc permeatin in Escherichia coli, Antimicrob Agents Chemother. 32: 438 (1988).
H. Nikaido and D.G. Thanassi, Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples, Antimicrob Agents Chemother. 37: 1393 (1993).
H. H. Yoshida, M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno, Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones, J Bacteriol. 172: 6942 (1990).
M.E. Cullen, A.W. Wyke, R. Kuroda, and L.M. Fisher, Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother. 33: 886 (1989).
M. Oram and L.M. Fisher, 4-quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction, Antimicrob Agents Chemother. 35: 387 (1991).
H. Yoshida, M. Bogaki, M. Nakamura, and S. Nakamura, Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli, Antimicrob Agents Chemother. 34: 1271 (1990).
H. Yoshida, T. Kojima, J. Yamagishi, and S. Nakamura, Quinolone-resistant mutations of the gyrA gene of Escherichia coli, Mol Gen Genet. 211: 1 (1988).
J.S. Wolfson and D.C. Hooper, Fluoroquinolone antimicrobial agents, Clin Microbiol Rev. 2: 378 (1989).
C.J.R. Willmott and A. Maxwell, A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex, Antimicrob Agents Chemother. 37: 126 (1993).
P. Heisig, H. Schedletsky, and H. Falkenstein-Paul, Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli, Antimicrob Agents Chemother. 37: 696 (1993).
E. Cambau, F. Bordon, E. Collatz, and L. Gutmann, Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid, Antimicrob Agents Chemother. 37: 1247 (1993).
H. Yoshida, M. Bogaki, M. Nakamura, L.M. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region of the DNA gyrase gyrB gene of Escherichia coli, Antimicrob Agents Chemother. 35: 1647 (1991).
J. Yamagichi, H. Yoshida, M. Yamayoshi, and S. Nakamura, Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli, Mol. Gen. Genet. 204: 367 (1986).
L.L. Shen, W.E. Kohlbrenner, D. Weigl, and J. Baranowski, Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes J. Biol. Chem. 264: 2973 (1989).
L.L. Shen, L.A. Mitscher, P.N. Sharma, T.J. O’Donnell, D.W.T. Chu, C.S. Cooper, T. Rosen, and A.G. Pernet. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model, Biochemistry 28: 3886 (1989).
H. Yoshida, M. Nakamura, M. Bogaki, H. Ito, T. Kojima, H. Hattori, and S. Nakamura, Mechanism of action of quinolones against Escherichia coli DNA gyrase, Antimicrob Agents Chemother. 37: 839 (1993).
T. Kirchhausen, J.C. Wang, and S.C. Harrison, DNA gyrase and its complexes with DNA: direct observations by electron microscopy, Cell 41: 933 (1985).
S. Sreedharan, M. Oram, B. Jensen, L.R. Peterson, and L.M. Fisher, DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli, J Bacteriol. 172: 7260 (1990).
Y. Wang, W.M. Huang, and D.E. Taylor, Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations, Antimicrob Agents Chemother. 37: 457 (1993).
H.E. Takiff, L. Salazar, C. Guerrero, W. Philipp, W.M. Huang, B. Kreiswirth, S.T. Cole, W.R. Jacobs, Jr., and A. Telenti. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 38: 773 (1994).
D.C. Hooper and J.S. Wolfson, Mechanisms of bacterial resistance to quinolones, in: “Quinolone Antimicrobial Agents,” Second Edition, D.C. Hooper and J.W. Wolfson, eds., American Society for Microbiology, Washington (1993).
D.C. Hooper, J.S. Wolfson, K.S. Souza, E.Y. Ng, G.L. McHugh, and M.N. Swartz, Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation, Antimicrob Agents Chemother. 33: 283 (1989).
K. Hirai, H. Aoyama, S. Suzue, T. Irikura, S. Iyobe, and S. Mitsuhashi, Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K12, Antimicrob Agents Chemother. 30: 248 (1986).
A.M. George and S.B. Levy, Gene in the major cotransduction gap of the Escherichia coli K-12 linkage map required for the expression of chromosomal resistance to tetracycline and other antibiotics, J Bacteriol. 155: 541 (1983).
S.P. Cohen, L.M. McMurry, D.C. Hooper, J.S. Wolfson, and S.B. Levy, Cross-resistance to fluoroquinolones in multiple antibiotic resistant (Mar) Escherichia coli selected by tetracycline and chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction, Antimicrob Agents Chemother. 33: 1318 (1989).
H. Hächler, S.P. Cohen, and S.B. Levy, marA, a regulated locus which controls expression of chromosomal multiple antibiotic resistance in Escherichia coli, J Bacteriol. 163: 5532 (1991).
S.P. Cohen, H. Hächler, and S.B. Levy, Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli, J Bacteriol. 175: 1484 (1993).
R.R. Ariza, S.P. Cohen, N. Bachhawat, S.B. Levy, and 13. Demple, Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli, J Bacteriol. 176: 143 (1994).
S.P. Cohen, L.M. McMurry, and S.B. Levy, marA locus causes decreased expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli, J Bacteriol. 170: 5416 (1988).
Hooper, D.C., J.S. Wolfson, M.A. Bozza, and E.Y. Ng, Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB, Antimicrob Agents Chemother. 36: 1151 (1992).
S.P. Cohen, D.C. Hooper, J.S. Wolfson, K.S. Souza, L.M. McMurry, and S.B. Levy, An endogenous active efflux of norfloxacin in susceptible Escherichia coli, Antimicrob Agents Chemother. 32: 1187 (1988).
V. Jarlier, L. Gutmann, and H. Nikaido, Interplay of cell wall barrier and ßlactamase activity determines high resistance to ß-lactam antibiotics in Mycobacterium chelonae, Antimicrob Agents Chemother. 35: 1937 (1991).
D.M. Livermore, Interplay of impermeability and chromosomal ß-lactamase activity in imipenem-resistant Pseudomonas aeruginosa, Antimicrob Agents Chemother. 36: 2046 (1992).
H. Yoshida, M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno, Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones, J Bacteriol. 172: 6942 (1990).
G.W. Kaatz, S.M. Seo, and C.A. Ruble, Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus, Antimicrob Agents Chemother. 37: 1086 (1993).
A.A. Neyfakh, V.E. Bidnenko, and L.B. Chen, Efflux-mediated multidrug-resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system, Proc Natl Acad Sci USA. 88: 4781 (1991).
I.T.,Paulsen and R.A. Skurray, Topology, structure and evolution of two families of proteins involved in antibiotic and antiseptic resistance in eukaryotes and prokaryotes - an analysis, Gene 124: 1 (1993).
E.Y. Ng, M. Trucksis, and D.C. Hooper, Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome, submitted (1994).
C.J. Soussy, J.S. Wolfson, E.Y. Ng, and D.C. Hooper, Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus, Antimicrob Agents Chemother. 37: 2588 (1993).
J.-I. Kato, Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki, New topoisomerase essential for chromosome segregation in E. coli. Cell 63: 393 (1990).
J.-I. Kato, H. Suzuki, and H. Ikeda, Purification and characterization of DNA topoisomerase IV in Escherichia coli, J Biol Chem. 267: 25676 (1992).
H. Peng and K.J. Marians, Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions, J Biol Chem. 268: 24481 (1993).
M. Trucksis, J.S. Wolfson, and D.C. Hooper., A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus, J Bacteriol. 173: 5854 (1991).
S. Hori, Y. Ohshita, Y. Utsui, and K. Hiramatsu, Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus, Antimicrob Agents Chemother. 37: 2278 (1993).
M.F. Parry, K.B. Panzer, and M.E. Yukna, Quinolone resistance: susceptibility data from a 300-bed community hospital, Am J Med. 87 (Suppl 5A): 125 (1989).
L.R. Peterson, Quinolone resistance in clinical practice: occurrence and importance, in: “Quinolone Antimicrobial Agents,” Second Edition, D.C. Hooper and J.W. Wolfson, eds., American Society for Microbiology, Washington (1993).
D.R. Schaberg, W.I. Dillon, M.S. Terpenning, K.A. Robinson, S.F. Bradley, and C.A. Kauffman, Increasing resistance of enterococci to ciprofloxacin, Antimicrob Agents Chemother. 36: 2533 (1992).
J. Blaser, B.B. Stone, M.C. Groner, and S.H. Zinner, Comparative study with enoxacin and netilmicin in a pharmacodynamie model to determined importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance, Antimicrob Agents Chemother. 31: 1054 (1987).
R.R. Muder, C. Brennen, A.M. Goetz, M.M. Wagener, and J.D. Rihs, Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center, Antimicrob Agents Chemother. 35: 256 (1991).
Y.C. Yee, R.R. Muder, M.H. Hsieh, and T.C. Lee, Molecular epidemiology of endemic ciprofloxacin-susceptilbe and -resitant Enterobacteriaceae, Infect Control Hosp Epidemiol. 13: 706 (1992).
H.M. Blumberg, D. Rimland, D.J. Carroll, P. Terry, and I.K. Wachsmuth, Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus, J Infect Dis. 163: 1279 (1991).
T.E. Daum, D.R. Schaberg, M.S. Terpenning, W.W. Sottile, and C.A. Kauffman, Increasing resistance of Staphylococcus aureus to ciprofloxacin, Antimicrob Agents Chemother. 34: 1862 (1990).
M.C. Raviglione, J.F. Boyle, P. mauriuz, A. Paublos-Mendez, H. Cortes, and A. Merlo, Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital, Antimicrob Agents Chemother. 34: 2050 (1990).
S.M. Smith, R.H.K. Eng, P. Bais, P. Fan-Havard, and F. Tecson-Tumang, Epidemiology of ciprofloxacin resistance among patients with methicillinresistant Staphylococcus aureus, J Antimicrob Chemother. 26: 567 (1990).
H.M. Blumberg, D. Rimland, J.A. Kiehlbauch, P.M. Terry, and I.K. Wachsmuth, Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage-nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolates, J Clin Microbiol. 30: 362 (1992).
G.L. McHugh, J.S. Wolfson, and D.C. Hooper, unpublished observations.
J.F. Acar, T.F. O’Brien, F.W. Goldstein, and R.N. Jones, The epidemiology of bacterial resistance to quinolones, Drugs 45 (Suppl 3): 24 (1993).
H.P. Endtz, G.J. Ruijs, B. van Klingeren, W.H. Jansen, T. van der Reyden, and R.P. Mouton, Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine, J Antimicrob Chemother. 27: 199 (1991).
J.M. Aguiar, J. Chacon, R. Canton, and F. Baquero, The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections, J Antimicrob Chemother. 29: 349 (1992).
E. Pérez-Trallero, M. Urbieta, D. Jimenez, J.M. García-Arenzana, and G. Cilla, Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections, Eur J Clin Microbiol Infect Dis. 12: 349 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hooper, D.C. (1995). Bacterial Resistance to Fluoroquinolones: Mechanisms and Patterns. In: Jungkind, D.L., Mortensen, J.E., Fraimow, H.S., Calandra, G.B. (eds) Antimicrobial Resistance. Advances in Experimental Medicine and Biology, vol 390. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9203-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9203-4_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9205-8
Online ISBN: 978-1-4757-9203-4
eBook Packages: Springer Book Archive